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Materials and Methods 
Biochemistry Methods 
Sf9 expression of A2AR 
DNA encoding a wild-type A2A adenosine receptor (ADORA2A or A2AR) insert ready in Bac-to-Bac vector was ordered from 
GenScript. The plasmid contained a C-terminal His6-tag and before that a TEV-cleavage site. Recombinant protein was 
expressed in Sf9 insect cells as detailed in Invitrogen’s Bac-to-Bac Baculovirus Expression System protocol. Sf9 cells were 
infected when the cell density was 1,5 x 106 and expressed for 48 hours. After expression cells were collected by 
centrifugation at 800 x g for 15 minutes and washed twice with PBS (phosphate-buffered saline), without Ca2+ and Mg2+, pH 
7.4 (PAA Laboratories GmbH). Cells were broken using nitrogen cavitation; 40 bar and 30 min. Then cells were collected by 
ultracentrifugation at 100 000 x g for 1 h, pellets were collected and stored at -80 oC for further use. 
Protein purification 
For nanodiscs, the pellet was resuspended in 25 mM phosphate buffer, 10 % glycerol, 100 mM NaCl and 0.1 mM 
Ethylenediaminetetraacetic acid (EDTA) with one protease pill in 5 g of cell pellet (Roche). 1% of n-dodecyl-β-D-
maltopyranoside (DDM) and 0.2 % of Cholesteryl hemisuccinate (CHS) was added and then incubated in a vertical shaker 
for 1 h. Then, NaCl was added for a final concentration of 500 mM. The prepared sample was centrifuged at 100 000 x g for 
30 min and the supernatant was subsequently collected.  
For protein purification we used Talon Metal Affinity Resin. First 1 to 1.5 ml of well mixed resin were pipetted into a 
container which can hold ten to twenty times the volume of the resin. The resin was centrifuged down at 700 x g for 2 min. 
The supernatant was disposed of and resin were washed with ten to twenty volumes of washing buffer consisting of 25 
mM sodium phosphate, pH 7.5, 10 % (w/v) glycerol, 500 mM NaCl, 0.1 % DDM. After a few minutes of gentle shaking the 
resin was centrifuged down again at 700 x g for 2 min. The protein supernatant from ultracentrifugation was added onto 
the resin and the mixture was left in a cold room at +4° C in a vertical shaker for 20 min, then the resin was again 
centrifuged down at 700 x g for 5 min and washed once with washing buffer for 10 min at +4° C and centrifuged again at 
700 x g for 5 min. The resin was moved to a gravitation column and allowed to settle down, washed in a three- to five-fold 
volume of washing buffer that contained 20 mM imidazole. Elution was performed directly into 1.5 ml Eppendorf tubes 
using washing buffer containing 150 mM imidazole. The samples were flash freeze and stored at -80° C for further use. 
Nanodisc preparation 
Two different kind of Membrane Scaffold Protein 1D1 (MSP1D1) were prepared one where the His-tag was removed using 
the TEV-cleavage site and another one, where no His-tag was attached. Both variants were expressed in E. coli using LB 
medium. Bacteria were incubated at +37° C and shaken at 180 rpm until an OD 600 of 0.8 was reached. Expression was 
induced by addition of 1 M Isopropyl--D thiogalactopyranosid (IPTG) to a final concentration of 1 mM. Cells were 
harvested by centrifugation for 30 minutes and 4000 rpm at +4° C, washed once using PBS buffer, centrifuged for 15 min at 
4000 rpm at +4° C and stored at -20° C for future use. Cells were then resuspended using MSP1D1 lysis buffer (40 mM 
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Tris/HCl pH 8.0, 300 mM NaCl, 1 % Triton X-100, 4 mM sodium azide), 4 ml/g of cells, spatula tip of MgCl2 and DNAse I and 
one protease pill (Roche) in 5 g of cells. Cells were then lysed by sonication. The sonicated cells were centrifuged for 1 hour 
at 100 000 x g and the supernatant was filtered with a 0.2 m syringe filter and then loaded to a Ni2+-sepharose column 2 
ml/min, equilibrated by MSP lysis buffer. After loading, the column was washed using 4 bed volumes of MSP lysis buffer 
then: 1) 40 mM Tris/HCl, pH 8.0, 300 mM NaCl, 50 mM sodium cholate; 2) 40 mM Tris/HCl, pH 8.0, 300 mM NaCl; 3) 40 mM 
Tris/HCl, pH 8.0, 300 mM NaCl, 50 mM imidazole. Protein was eluted using MSP elution buffer (40 mM Tris/HCl, pH 8.0, 
300 mM NaCl, 300 mM imidazole, 4mM sodium azide) and fractions containing protein were collected. At this point 
MSP1D1 without His-tag was prepared as follows: after determination of MSP1D1 concentration 1 mg of TEV-protease was 
added to every 5 mg of protein and was subjected to dialysis in MSP-His-tag cleavage buffer (50 mM Tris/HCl, pH 8.0, 0.5 
mM EDTA, 1mM DTT) in 6 kDa molecular weight cut-off (MWCO) membrane at room temperature overnight. On the next 
day the dialysis was continued against 20 mM Tris/HCl, pH 8.0, 150 mM NaCl, at +4° C overnight. After this sodium cholate 
was added to a final concentration of 50 mM. The Ni2+-sepharose loaded column was equilibrated using MSP purification 
buffer (20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 50 mM sodium cholate). MSP was loaded to the column and eluted fractions 
were collected and finally dialyzed against nanodisc buffer (20 mM Tris/HCl, pH 7.4, 100 mM NaCl). The concentration of 
MSP1D1 was measured and we prepared 1 mg/ml vials of 1 ml volume, flash froze them using liquid nitrogen and stored 
them at -80° C. To prepare MSP1D1 with His-tag, the expressed protein was simply dialyzed once after the first Ni2+ 
Sepharose loaded column against nanodisc buffer, measured and stored after that. 
For the preparation of loaded nanodiscs, MSP1D1 scaffold protein and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) lipids from Avanti Polar Lipids were used. Nanodiscs with adenosine A2AR were prepared using molar ratios 
1:25:750, A2AR, MSP1D1 and POPC respectively. First, samples were incubated on ice for one hour using 20 mM Tris/HCl, 
pH 7.4, 100 mM sodium cholate, 10 mg/ml of lipids and 0.1 % DDM. Washed and swelled Bio Beads (Biorad) were added 
0.5 g per ml of sample and incubated for 90 min at +4° C in a 
syringe filter and loaded on a 10/300 sepharose column and eluted in 1 ml fractions using the SEC buffer. 
Loaded discs were purified using Talon Metal Affinity Resin using 25 mM phosphate buffer with 150 mM NaCl. Eluted by 
250 mM imidazole, the sample was desalted and the buffer was exchanged using PD Mini Trap G-25 (GE Healthcare) gel 
filtration columns. G25 columns were first equilibrated with twice the column volume using 25 mM phosphate buffer pH 
7.0 and 150 mM NaCl in 100 % deuterium oxide. 0.5 ml of sample was introduced into the column and then eluted using 1 
-0.5 ml, 30 kDa viacons, 
first washed with 0.1 M NaOH and with 25 mM phosphate buffer pH 7.0 and 150 mM NaCl in 100 % deuterium oxide 
before use. 
For the negative control we prepared empty discs without A2AR. The protocol was identical to the protocol to prepare 
loaded nanodiscs expect for a change of the MSP:POPC stoichiometry. For loaded nanodiscs, the ratio was 1:30, while for 
empty ones it was 1:35. Empty discs were also purified to remove free lipids. The buffer was exchanged and the discs were 
concentrated to the same final concentration as in the case of the loaded ones. Concentrations of final samples were 
adjusted by absorbance of 280 nm (A280) using extinction coefficients as follows; for A2AR 57255 and for MSP1D1 18450, 
assuming that there is one receptor per one nanodisc and one disc contains two MSP proteins. 
 
Figure S1. On the left; Western-blot picture of A2AR in sf9 insect cell extract, detected using anti-His antibody. Middle; size exclusion 
chromatography elution curve of A2AR incorporated with MSP1D1 nanodiscs of Superdex 200 increase 10/30 GL column, where calibration of 
column has been made using standart marker proteins as follows; F) Ferritin, 440 kDa and 10,97 ml, C) Conalbumin, 75 kDa and 14,90 ml, 
CA) Carbonic Anhydrase 29 kDa and 16,83 ml, R) Ribonuclease A 13,7 kDa and 19,53 ml. On the right; SDS-PAGE gel of 4 M NMR 
sample; A2AR Adenosine is visible around 46 kDa, MSP1D1 below 25 kDa. Due low concentration, the receptor is not visible in SDS-PAGE 
gel of SEC fractions. 





Stock solutions of all ligands were prepared in DMSO-d6 as solvent at a concentration of 32 mM, except for the stock 
solution of XAC which had a concentration of 7 mM due to a limited solubility. The internal standard and chemical shift 
reference TSPA-d6 was dissolved in D2O at a concentration of 2 mM. These stock solutions were pipetted to a nanodisc 
solution previously diluted by buffer. The final concentration of the nanodiscs after the addition of the ligands was 4 µM. In 
all experiments not involving SYN115, the ligand concentration of caffeine, PQA and ZMA was 300 µM. In experiments with 
SYN115, the concentration was 200 µM for PQA, ZMA and SYN. Later, XAC was added to the samples up to a total 
concentration of 50 µM. The concentration of TSPA was in all experiments 20 µM. All samples were filled into 3 mm NMR-
tubes with a total sample volume of 120 µL. 
NMR Experiments 
All NMR experiments were conducted at 700 MHz, either on a Bruker AVANCE III spectrometer equipped with an Oxford 
magnet and a Bruker CryoProbe Prodigy, or on a Bruker AVANCE I spectrometer equipped with a Bruker US magnet and a 
Bruker CryoProbe. All measurements were conducted at 298 K. 
One-dimensional proton spectra were recorded with a relaxation time of 2 s. The residual water signal was suppressed by 
presaturation. The signal was acquired for 487 ms with 8192 data points. 
The STD-experiments were set up with a relaxation time of 2 s and a selective saturation time of 3 s. For this purpose, a 
cascade of Gaussian pulses with a length of 20 ms was applied. The on-resonance frequency was set to -1 ppm and the off-
resonance frequency to 50 ppm. A 3-9-19 watergate pulse scheme was used for water suppression. The FID was recorded 
with 4096 data points and a length of 243 ms. The presence or absence of the TSPA-d6 signal and the signal of DMSO-d6 in 
the STD spectra was used as a control of the experimental setup. In all recorded STD experiments with nanodiscs neither of 
the mentioned substances gave rise to a STD signal. 
For the INPHARMA measurements, a NOESY experiment with water presaturation was used. 4096 data points in the direct 
dimension and 600 in the indirect dimension were acquired, which corresponds to an acquisition time of 243.3 ms and 
35.6 ms, respectively. The relaxation time was 2s and a mixing time of 300 ms was measured in all experiments. 
Spectral Analysis  
The chemical shift in all spectra was referenced to the residual protons of DMSO-d6, which was added to the samples via 
the stock solutions of the ligands. The chemical shift was set to 2.70 ppm. The methyl signal of internal standard TSPA-d6 
showed in some samples minor chemical shift changes, specially, when the free lipid concentration was high. The chemical 
shifts of all ligands is summarized in table S1. 
Table S1. Chemical shift assignment of the studied ligands. 
Caffeine  PQA  SYN  ZMA  XAC  
Resonance C. S. 
[ppm] 
Resonance C. S. 
[ppm] 
Resonance C. S. 
[ppm] 
Resonance C. S. 
[ppm] 
Resonance C. S. 
[ppm] 
1 7.91 1 2.02 1 1.32 1 7.76 1 3.64 
2 3.97 2 3.72 2 1.72 2 6.70 2 3.22 
3 3.37 3 7.50 3 3.53 3 7.20 3 4.74* 
4 3.55 4 7.39 4 3.80 4 3.63 4 7.14 
  5 7.39 5 3.20 5 2.87 5 7.91 
  6 7.62 6 3.99 6 7.21 6 3.93 
    7 7.07 7 6.83 7 1.65 
    8 3.99   8 0.95 
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        9 4.08 
        10 1.81 
        11 0.98 
*based on the cross peaks in the recorded NOESY experiments at XAC concentrations above 200 µM 
STD experiments and results 
In order to compare the STD experiments, all signals of the ligands without overlap or artifacts were integrated and 
normalized to the signal intensities in the off resonance spectra. In the next step, the experimental values of the three 
samples - loaded discs without XAC (ST2), empty discs without XAC (ST1) and loaded discs with XAC (ST3) - , were 
compared. The normalized integrals of the sample with loaded discs and without XAC (ST2) were defined as 100 %. With 
this, the values for the other samples were calculated. We expected the following results for our STD measurements:  
Table S2. Comparison of the measured STD intensities between the three samples: ST1 - loaded discs without XAC, ST2 - empty discs 
without XAC, ST3 - loaded discs with XAC. The sample with loaded discs and without XAC was used as reference. 




e - 1 
C
affein
e - 2 
C
affein



















 – 6 
ZM
A
 – 1 
ZM
A









 – 5 
ZM
A















Loaded discs w/o 
XAC 
100 100 100 100 100 100 100 100 100 100 100 100   100 100 100 
Empty discs w/o 
XAC 
8 37 33 158 94 97 110 105 110 97 104 95   26 115 102 
Loaded discs w/ 
XAC 
120 117 82 75 89 86 87 85 78 80 69 86   106 84 80 
 
Neither with empty nanodiscs (ST1) nor with loaded discs in the presence of XAC (ST3) STD signals should be observable for 
CAF, PQA, and ZMA due to the lack of a receptor and an accessible binding pocket, respectively. Opposite to our 
expectations, for all three ligands, STD signals were observed in both cases, although none were observed in buffer alone 
without nanodiscs. Therefore unspecific interactions between the scaffold protein and/or the lipids and the ligands must 
take place. Nevertheless, an accessible A2AR binding site (ST2) should add to these measured unspecific STD signals. Yet, 
out of the three ligands, only CAF showed four times stronger STD signals. In contrast, the presence of XAC (ST3) had no 
effect on the STD signals of CAF, but the signals of PQA and ZMA were reduced by approximately 20%. Based on these 
inconclusive findings, we discarded the STD experiments in the analysis of our system. 
Data preparation for the SpInpharma calculations 
The INPHARMA data was prepared in the following steps: Based on the assignment (table S 1) all cross and diagonal peaks 
were assigned and integrated.[1] All ligands had in all samples cross peaks which had the same sign as the diagonal peaks. 
This suggests an interaction between the ligands and the unloaded nanodiscs. In a consecutive step, the signals had to be 
normalized in order to compensate non-equilibrium conditions due to limited relaxation delays between scans and 
sensitivity changes between different samples and titration steps. For this purpose, the integral values were divided by the 
overall magnetization of each resonance, which corresponds to the sum of all peaks with the same frequency in the 
indirect dimension (F1). 
This measure presents a few difficulties. Some peaks were overlapping with each other or impurities. Two of these are the 
peaks off resonance 3 and 6 of ZMA around 7.20 ppm and 7.21 ppm, respectively. In the direct dimension, both are 
overlapping but still distinguishable (Figure S1). Therefore the volumes had to be approximated based on the two 
integration areas (Figure S1 A and B). The area around 7.21(A) is one half of the doublet of resonance 6. Therefore it was 
SUPPORTING INFORMATION          
6 
 
multiplied by two, in order to obtain the full integral of resonance 6.Accordingly, the integral around 7.21 (A) was 
subtracted from the integral around 7.20 ppm (B) to obtain the integral of resonance 3. 
 
Figure S2: Exemplary section of a NOESY spectrum of ZMA. The peaks of resonances 3 and 6 are overlapping with a chemical shift of 7.200 
ppm and 7.205 ppm, respectively. Resonance 6 is a doublet with its peaks at 7.200 and 7.210 ppm. A and B are the integration areas which 
were used to calculate the separated integrals of resonance 3 and 6. 
In the indirect dimension, both resonances cannot be distinguished. Therefore, the overall integral of both was taken and 
split relative to the intensity ratios of the corresponding signals on the other half of the diagonal. In case of the diagonal 
peak, the proton ration of 2:1 was used to divide the integral. 
Furthermore, the diagonal peaks of resonances 2 of PQA and 4 of ZMA are overlapping with signals from some impurities 
in the sample solution. This made it impossible to calculate the overall magnetization for these resonances. Hence, it was 
necessary to calculate the average of the overall magnetization per proton for each ligand based on the other resonances. 
These values were used to extrapolate the overall magnetization of these two resonances. 
In a next step, the difference of the normalized signals between the samples a) with (ST2) and without XAC (ST3) and b) 
with (ST2) and without (ST1) A2AR was taken in order to remove contributions which are not related to the binding pocket. 
For this procedure to work, some corrections had to be made. Due to noise and low signal intensities, some integrals were 
negative and were therefore set to 0. Another effect of taking the difference between two spectra was that the diagonal 
peaks canceled each other out or became even negative. For the SPINPHARMA software, it was necessary to replace these 
values since the software requires normalized integrals. The sum of all normalized integrals (cross and diagonal peaks) of 
one resonance in the F1 dimension should equal 1, which is not true after the subtraction of the signals. Therefore, all 
differences of the normalized cross peaks in the indirect dimension were summed up and subtracted from 1, in order to 
obtain the volume of the diagonal peak. 
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In a last step, the spectrum was reflected at the diagonal (F1 = F2). This is because the SPINPHARMA software only allows 
normalization along the direct dimension. 
Detail of the NOESY spectra of PQA and SYN 
 
Figure S3: NOESY spectra showing cross peaks between SYN and PQA. Top panel with empty nanodiscs (ST1), middle panel with A2AR 
loaded nanodiscs (ST2) and bottom panel with with A2AR loaded nanodiscs in the presence of XAC (ST3). (PQA:SYN:XAC – 200:200:50 µM)  
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Detail of the NOESY spectra of ZMA and SYN 
 
Figure S4: NOESY spectra showing intraligand NOE’s of SYN and one interligand NOE between SYN and ZMA. Top panel with empty 
nanodiscs (ST1), middle panel with A2AR loaded nanodiscs (ST2) and bottom panel with A2AR loaded nanodiscs in the presence of XAC  
(ST3). The numbers beneath the peaks indicate the corresponding normalized volumes. (ZMA:SYN:XAC – 200:200:50 µM) 
Radioligand Binding 
Cell membrane preparations 
Sf9 insect cells recombinantly expressing human A2AR were broken using nitrogen cavitation and cells were collected by 
centrifugation at 100 000 x g for 60 min. The cell pellet was collected, resuspended and washed with 25 mM phosphate-
buffered saline (PBS, pH 7.5, consisting of 100 mM NaCl in 100% D2O) then centrifuged at 50 000 x g for 30 min; this was 
done three times. After washing, samples were frozen and stored at -80° C. Sf9 cell membrane preparations were washed 
three times with ice-cold 50 mM Tris- buffer at pH 7.4, then centrifuged at 48,000 g for 30 min each time to remove the 
NaCl in the storage buffer. After the last centrifugation step the obtained cell pellets were resuspended in 3 ml of 50 mM 
Tris-buffer at pH 7.4 and stored at -80° C. The protein content was determined by the Lowry method.[2] CHO cell membrane 
preparations recombinantly expressing the human A2AR (CHO-hA2A or CHO-HA-hA2A) were prepared as previously 
described.[3] For affinity measurement of eticlopride, L2 and SYN-115 human embryonic kidney (HEK) cell membranes 
recombinantly expressing human A2ARs obtained from Perkin Elmer (HEK-hA2A, Perkin Elmer, RBHA2AM400UA) were used. 
Radioligand binding assays at human adenosine A2A receptors  
For radioligand binding assays the tritiated A2AR-selective antagonist [³H]MSX-2 and the tritiated A2AR-selective agonist 
[³H]CGS21680 were used.[3] The previously determined Kd-values of the employed radioligands at the human adenosine A2A 
receptor are as follows: [³H]MSX-2, 7.29 nM; [³H]CGS21680, 25.0 nM. 
Competition binding experiments with [3H]MSX-2 were performed in a final volume of 400 µl containing 4 µl of test 
compound dissolved in DMSO, 200 µL of buffer (50 mM Tris-buffer, pH 7.4), 100 µl of radioligand solution in the same 
buffer (final concentration 1 nM), and 100 µl of Sf9 insect cell membrane preparation expressing the human A2AR (50 µg 
protein per vial in 50 mM Tris-buffer containing 2 units (U)/ml of adenosine deaminase (ADA), or 100 µl of HEK cell 
membrane preparation expressing the human A2AR (8 µg protein per vial containing 2U/ml of ADA), or 100 µl of CHO cell 
membrane preparation expressing the human A2AR (50-100 µg protein per vial containing2U/ml ADA) respectively. ADA 
was added in order to convert adenosine present in the preparation to inosine since adenosine would otherwise interfere 
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with radioligand binding. Nonspecific binding was determined in the presence of the A2AR antagonist CGS15943 (final 
concentration 10 µM). Competition binding experiments with [3H]MSX-2 in the presence of 100 mM NaCl (final 
concentration) were performed in a final volume of 400 µl containing 4 µl of test compound dissolved in DMSO, 100 µL of 
buffer (50 mM Tris-buffer, pH 7.4), 100 µL of NaCl-containing buffer (400 mM NaCl, 50 mM Tris-buffer, pH 7.4), 100 µl of 
radioligand solution in 50 mM Tris-buffer (final concentration 1 nM), and 100 µl of Sf9 cell membrane preparation 
containing the human A2AR (50 µg protein per vial in 50 mM Tris-buffer). Nonspecific binding was determined in the 
presence of CGS15943 (final concentration 10 µM). After an incubation time of 30 min at rt, the assay mixture was filtered 
through GF/B glass fiber filters which were previously incubated in 0.3% polyethyleneimine (PEI) solution for 30 min using a 
Brandel cell harvester (Brandel, Gaithersburg, MD, USA). Filters were washed three times with ice-cold 50 mM Tris-HCl 
buffer, pH 7.4 (3-4 ml each). Then filters were transferred to scintillation vials, incubated for 9 h with 2.5 ml of scintillation 
cocktail (Luma Safe, Perkin Elmer), and counted in a liquid scintillation counter (Tri-Carb 2810 TR) with a counting efficiency 
of 52%. Three separate experiments were performed for determination of the IC50 values. Data were analyzed with the 
program GraphPad Prism, Version 4.1 (GraphPad Inc., La Jolla, CA). 
Radioligand binding assays at human A2A receptors reconstituted in nanodiscs 
A preparation of human A2AR reconstituted in nanodiscs (250 µl in 25 mM phosphate-buffered saline (PBS), pH 7.5, 
consisting of 100 mM NaCl in 100% D2O, 4.7 µM), was divided into 50 µl aliquots and stored at -80°C until use. For the 
assay pre-test the protein was diluted 1:2 with 50 mM Tris-buffer pH 7.4 and for further tests the protein aliquots were 
diluted 1:10 with 50 mM Tris-buffer pH 7.4. Competition binding experiments with [3H]MSX-2 were performed in a final 
volume of 400 µl containing 4 µl of test compound dissolved in DMSO, 200 µL buffer (50 mM Tris-buffer, pH 7.4), 100 µl of 
radioligand solution in the same buffer (final concentration 1 nM), and 100 µl of a suspension of human A2AR in nanodiscs. 
All other conditions were as described above for A2AR expressed in mammalian cells.  
Agonists such as NECA and CGS21680 typically show a higher affinity for the receptor conformation that is labelled by an 
agonist radioligand (high affinity conformation for agonists) than for the conformation that is labelled by an antagonist 
radioligand. Therefore, the agonists NECA and CGS21680 display significantly higher affinity versus the agonist radioligand 
[3H]CGS21680 as compared to the antagonist radioligand [3H]MSX-2. In contrast, antagonists typically bind with identical 
(neutral agonists) or similar affinity (inverse agonists) to the receptor conformations labelled by agonist or antagonist 
radioligands.[4] 
Table S3. Affinities of the agonists NECA and CGS21680 determined versus antagonist ([3H]MSX-2) and agonist ([3H]CGS21680) 
radioligands at human A2AR expressed in CHO-cells, or in Sf9 insect cells, respectively. 




Ki/KD* value ± SEM (nM) 
 NECA CGS21680 
 




447 ± 148 
 
 














167 ± 48* 
 




64.0 ± 9.8ns 
 
27.1 ± 6.8ns 
      
    *p < 0.05 
 ***p < 0.001 
   ns = not significant 
Modulation of A2A receptor binding by sodium ions 
In the presence of NaCl (100 mM) the agonist curves (for NECA and CGS21680) determined at human A2AR expressed in Sf9 
insect cells versus the antagonist radioligand [3H]MSX-2 were shifted to the right (Figure S4). The effect was more 
pronounced for NECA (6-fold shift) than for CGS21680 (2-fold shift) indicating that both agonists may prefer somewhat 
different receptor conformations. As expected, no NaCl shift was observed for CGS21680 versus the agonist radioligand 
[3H]CGS21680. These results clearly indicate that the A2AR expressed in Sf9 insect cells is functional.[5] 
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Figure S5. Competition binding experiments of the agonists (A) NECA, and (B) CGS21680 versus the A2A-selective antagonist radioligand 
[³H]MSX-2 (1 nM) at human A2A receptors expressed in Sf9 insect cells in the absence and in the presence of 100 mM NaCl.  
(A) The calculated IC50-values for NECA were 190 ± 55 nM (without NaCl) and 1160 ± 280 nM (in the presence of 100 mM NaCl, *p < 0.05, n 
= 3 ± SEM, 6-fold shift) 
(B) The calculated IC50-values for CGS21680  were 673 ± 24 nM (without NaCl) and 1440 ± 480 nM (in the presence of 100 mM NaCl, n = 3 ± 
SEM, 2-fold shift). 
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Figure S6. Competition binding experiments of the agonists NECA and CGS21680 versus the A2A-selective agonist radioligand 
[³H]CGS21680 (5 nM) at human A2A receptors expressed in Sf9 insect cells (n=3, performed in single points). 




























Figure S7. Competition binding experiment of the A2A-antagonist XAC versus the A2A-selective antagonist radioligand [³H]MSX-2 (1 nM) at 
human A2AR reconstituted in nanodiscs. A single experiment was conducted and a Ki value for XAC of 0.650 nM was determined which is 
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Figure S8: Competition binding experiment of PQA versus the A2AR antagonist radioligand [³H]MSX-2 at human A2AR expressed in HEK293 
cells (n=3). For PQA a Ki value of 8.65 ± 0.79 µM was determined.  
 






























Figure S9: Competition binding experiment of SYN-115 versus the A2A antagonist radioligand [³H]MSX-2 at human A2A receptors expressed in 
HEK293 cells (n=3).A Ki value for SYN-115 of 5.17 ± 1.03 nM was determined. 
Computational Methods 
Generation of input structure for molecular dynamics simulations 
Overall, 12 X-ray structures were downloaded from the Protein Data Bank,[6] (PDB entries 2YDO, 2YDV, 3EML, 3PWH, 3OAK, 
3REY, 3RFM, 3UZA, 3UZC, 3VG9, 3VGA and 4EIY) and were used as starting points for the computational investigations. 
These structures represent different thermostabilized mutants of A2AR or chimera structures, in which A2AR is fused with 
another protein for easier crystallization. In addition some are partly co-crystallized with agonists and antagonists including 
the ligands ZMA, XAC and caffeine also used in this study. In order to make these structures comparable to the NMR 
measurements performed on the wild-type protein, the wild-type sequence was homology modelled taking the X-ray 
structures as templates one after another. Modeller 9.10,[7,8] was used with standard parameters and the flexible C-
terminus and some amino acids from the N-terminus, for which no information was available, were removed. Missing 
loops, e.g. which were cut out to attach a second protein to form the chimera, were also modelled in this step. In this way, 
we ended up with 12 wild-type starting structures from Gly5 to Ala317. These were then placed into a homogeneous lipid 
bilayer using the Membrane Builder,[9] part of the CHARMM-GUI web service. Two preprocessing steps had to be 
performed before using the web interface. 1) The Orientations of Proteins in Membranes (OPM) database provides sets of 
coordinates for membrane proteins from the PDB, which are correctly aligned to the hydrocarbon core of the lipid bilayer 
to be used directly in the Membrane Builder. To generate the same orientation for our modelled wild-type structures, the 
generated homology models were aligned on the corresponding PDB structures provided by the OPM database using the 
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Molcad II program,[10] by minimizing the distance between Cα atoms. 2) Ligand structures were extracted from the PDB 
files, protonated by the software SPORES,[11] and stored as mol2-files to guarantee correct protonation and bonding states. 
The following  5 STEPs were then performed using the interface: After upload of one of the wild-type structures to the web 
interface in PDB format, parameters for the protein and ligand were created (STEP 1). Disulfide bridges were created 
manually using the functionality of the web interface. To position the protein correctly in the membrane, the membrane 
was formed out of POPC molecules forming a rectangular unit cell and the minimal number of lipids around the protein in 
the x- and y-directions (the z-direction corresponds to the direction perpendicular to the membrane surface) was set to 2.0 
(STEP 2). The water thickness was set to 25.0 Å. 0.15 M KCl was added representing physiological conditions (STEP 3). After 
preparing the different components first (STEP 4 of Membrane Builder) and assembling the components (STEP 5) including 
the energy minimization steps performed automatically by the Membrane Builder, the resulting files were downloaded 
without further equilibration of the system. The complete system provided as a PDB file by Membrane Builder was then 
used as input for the molecular dynamics simulations.  
Molecular Dynamics Simulations 
Molecular dynamics (MD) calculations were done with the AMBER 12 suite of programs.[12] Before starting these 
simulations, the residue names of the lipid molecules had to be translated into AMBER format using 
charmmlipid2amber.py. The protein and lipid parameters were taken from the modified version of the Cornell et al. force 
field,[13] (parm12SB) and from the AMBER lipid force field (lipid14),[14] respectively. The ligands were parameterized using 
the general AMBER force field (GAFF),[15] and AM1bcc charges using the ANTECHAMBER program.[16] After the LEAP 
program generated the parameter and coordinate files for the complete system including protein, ligand, lipids, ions and 
water molecules, the box dimensions were manually corrected to the values identified by Membrane Builder. In all 
simulations the particle mesh Ewald (PME) method was used to treat long-range electrostatic interactions and the SHAKE 
method,[17] to constrain bond lengths of bonds involving hydrogen atoms. The time step was set to 2 fs with a non-bonded 
cutoff of 10 Å. 
All systems were first minimized by up to 20000 steps to account for differences in the AMBER and CHARMM force fields, 
since the latter was used in Membrane Builder for the lipid bilayer. The heating to 300 K was performed in two steps first 
from 0 to 100 K during 50 ps and then from 100 to 300 K during 1 ns of NVT-MD with harmonic restraints and with force 
constants of 10 kcal mol-1 Å-2 on the membrane, protein and ligand. To pre-equilibrate the membrane and relaxing the 
pressure to 1 bar, NPT-MD simulations were performed for 10 ns. The restraints on the protein and ligand were kept 
during this first equilibration step. Finally, the complete system was again equilibrated for another 10 ns slowly reducing 
the restraints on the protein and ligand. A production run of 100 ns followed and snapshots of the simulation were written 
out every 1 ps resulting in 100,000 complex structures for each of the 12 X-ray structures representing a thermodynamic 
ensemble available for further analysis. 
Pose prediction of ligands without X-ray structure 
For the ligands PQA and SYN, no X-ray structures are available up to now. Therefore, complex structures had to be 
proposed in order to be able to back-calculate INPHARMA spectra. Since exploring the complete conformational space to 
find the correct ligand pose is too time consuming using MD, faster but also more approximate methods were used to 
create first candidates of ligand poses. We used two different approaches: the docking program PLANTS,[18] and the 
alignment tool pharmacophore.[19] For both, the standard parameters were kept. PLANTS tries to fit the ligand into the 
active site of the protein by optimizing a score evaluating the steric fit, hydrogen bond and lipophilic interactions. Due to 
the flexibility of A2AR, all 12 X-ray structure were used separately in this docking approach and the active site was defined 
by the corresponding ligands from which X-ray exist. PharmACOphore aligns one flexible ligand onto a fixed ligand by 
matching pharmacophoric features like ring systems and hydrogen bond acceptors and donors. The ligands XAC and ZMA 
were used as fixed ligands using the conformation seen in their X-ray structures in complex with the mutated forms of A2AR 
as described above. PQA and SYN were aligned by optimizing the coordinates of the center of mass simultaneously to the 
torsion angles of single bonds. The resulting poses from both approaches were manually inspected. Since the protein 
adapts specifically to every ligand, PQA and SYN cannot be fit into the active site of smaller ligands by the docking tool or 
only show a limited number of favorable interactions. These structures were not considered further. Large steric overlaps 
were often seen for the poses proposed by pharmACOphore and these structures were also rejected. This selection 
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resulted in 3 PQA complex structures all resulting from the docking approach and 1 reasonable SYN structure from the 
pharmACOphore approach. For these remaining poses, the same MD protocol as described above was executed generating 
thermodynamic ensembles (again 100,000 snapshots were stored), which can then be validated by the agreement 
between the experimental and back-calculated spectra. 
Comparison of experimental and back-calculated INPHARMA spectra 
As described in Skjærven et al.,[20] a large number of complex structures should be used in the SpinPharma calculations to 
identify the correct poses. This is due to the fact that the back-calculated volumes of the INPHARMA peaks are very 
dependent on the proton-proton distances. In Onila et al.,[21] PLANTS was used to predict the ligand poses by optimizing a 
combination of the standard scoring function and a score describing the agreement of the experimental and theoretical 
spectra. Due to the large flexibility of the protein, this latter approach cannot be used here since the protein is kept rigid in 
the docking. Therefore, we follow another approach here: Due to the finite temperature and measuring time of the 
experiment, the experimental volumes don’t result from a single structure but from the thermodynamic ensemble of 
structures. This ensemble would also be obtained, in the ideal case, by all the structures generated during a very long MD 
simulation. With such optimal ensembles for both ligands, we could back-calculate the volumes of the INPHARMA peak for 
each pair of complex structures and should be able to get the best agreement with the experiment by comparing the 
calculated volumes averaged over all complex structures taken from the MD simulation with the experimental ones. It is 
clear that the 100 ns simulations of this large and very flexible system are far from an exhaustive ensemble. Nevertheless, 
even the structures of the partial ensembles of the correct ligand poses should, on average, show better agreement with 
the experiment than all other possible poses. As a proof-of-concept, we took 400 complex structures for each ligand from 
the snapshots from the simulations (every 250 ps) and calculated the Pearson correlation coefficient between the 
experimental and back-calculated volumes of the INPHARMA signals for each pair of a ZMA and PQA complex structure 
resulting in 160 000 values. The back-calculated values were obtained with the SpInpharma program using the two-state 
model. The affinity value of ZMA were taken from literature,[22] and for PQA affinity were measured (Figure S6). The 
correlation time of the nanodiscs were calculated with Stoke's law using the following parameters; disc diameter: 9.6 
nm,[23, 24] viscosity of deuterated water: 1.1 cP and a temperature of 298 K. An example input file is given in Figure S10.  
 
Figure S10: Example input file for the SpInpharma calculation for PQA and ZMA based on structures taken from the MD simulations. 
The resulting correlation coefficients for the best three docking structures of PQA are visualized as heat maps in Figure S11. 
For these calculations, the experimental values were generated using A2AR loaded disc volume integrals before and after 
XAC competition. To see changes occurring during the simulations, the values are arranged in a temporal order of the PQA 
and ZMA simulation in the x- and y-dimension, respectively. It can be clearly seen that the used ZMA structure has only a 
very weak influence on the correlation coefficient (vertical lines of very similar color). In contrast, significant changes can 
be seen between the different PQA simulations but also when comparing different time steps of the same simulation. 
Simulation 1 starts with correlation coefficients around 0 but these improve considerably during the first quarter of the 
simulation. Since the starting structure generated by docking or the pharmACOphore approach are very approximate, it is 
not unexpected that these show no agreement with the experiment. The MD simulation then optimizes the fit of the ligand 
into the binding site, which is verified by the improved correlation coefficient. The other two simulations show only very 
small changes over the course of the simulation. Simulation 3 even shows a worsening at the end of the simulation. 
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Overall, the pcc values are also slightly and significantly worse for simulation 2 and 3 compared to simulation 1, 
respectively. This can also be seen in the histograms of the correlation coefficients shown in Figure S12 and S13. To 
account for the fact that the simulation is not fully equilibrated at the start of the production run, i.e. large changes in the 
ligand structures are seen in the beginning of the simulation (see above), the histograms for only the last 60 ns of the 
simulations are given in the main document. If the empty disks are used as reference, the same result is obtained that 
simulation 1 gives on average the best correlation coefficients followed by simulation 2 (Figure S11). Simulation 3 again 
shows very bad correlation coefficients. Overall, the differences are, however, less pronounced as with the XAC titration 
reference. Additionally, the large improvement in simulation 1 cannot be seen with the empty nanodisc reference (data 
not shown). 
 
Figure S11: Heat map representing the Pearson correlation coefficients (PCC) comparing the experimental and back-calculated volumes of 
the INPHARMA signals. The values are arranged in a temporal order of the PQA and ZMA simulation in the x- and y-dimension, respectively. 
The three subfigures correspond to the three starting structures of PQA shown in the main document. (red) PCC = -1, (black) PCC = 0, (blue) 
PCC = 1 
 
 
Figure S12: Histogram of Pearson correlation coefficients (PCC) comparing the experimental and back-calculated volumes of the 
INPHARMA signals of ZMA and PQA for the full 100 ns of the MD simulation without experiment restraints. The 160 000 calculated values 
are binned into intervals of 0.1 and the corresponding percentage of the total values calculated. A, B and C are based on the three different 
structures of PQA (see main text). The experimental values were taken from difference of the XAC titration. 
 
 
Figure S13: Histogram of Pearson correlation coefficients (PCC) comparing the experimental and back-calculated volumes of the 
INPHARMA signals of ZMA and PQA for the full 100 ns of the MD simulation without experiment restraints. The 160 000 calculated values 
A B C 
A B C 
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are binned into intervals of 0.1 and the corresponding percentage of the total values calculated. A, B and C are based on the three different 
structures of PQA (see main text). The experimental values were taken from the difference between empty and loaded discs. 
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